Okoedoh Osazuwa

Mr. Okoedoh Osazuwa


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PCPatricia Comella-del-Barrio
Patricia Comella-del-Barrio
JBJohn Samson Bimba
John Samson Bimba
RARamota Adelakun
Ramota Adelakun
KKKonstantina Kontogianni
Konstantina Kontogianni
BMBarbara Molina-Moya
Barbara Molina-Moya
JDJose Dominguez
Jose Dominguez
There is a need for diagnostics for tuberculosis (TB) that are easy to use, able to screen non-sputum samples, and able to provide rapid results for the management of both immunocompromised and immunocompetent individuals. The Fujifilm SILVAMP TB LAM (FujiLAM) assay, a new non-sputum based point of need test for the diagnosis of TB, could potentially address most of these needs. We evaluated the performance of FujiLAM in HIV positive and HIV negative patients with presumptive TB attending three district hospitals in Nigeria. Consecutive patients were asked to provide urine samples on the spot, which were tested with FujiLAM. The results were compared against a positive culture and/or Xpert MTB/RIF as the reference standard. Forty-five patients had bacteriologically confirmed TB, and 159 had negative culture and Xpert MTB/RIF (no TB). The FujiLAM test was positive in 23 (sensitivity 65.7%, 95% CI = 48–80) HIV negative and seven (70%, 95% CI = 35–92) HIV positive patients with bacteriological confirmation of TB. FujiLAM was negative in 97 (specificity 99.0%, 95% CI = 94–100) HIV negative and 56 (93.3%, 95% CI = 83–98) HIV positive patients without TB. The FujiLAM test has good diagnostic accuracy for considering its application in both HIV positive and HIV negative patients with TB.

23 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NTNadiia Tytarenko
Nadiia Tytarenko
JBJohn Samson Bimba
John Samson Bimba
DVDídac Vulcano
Dídac Vulcano
PCPatricia Comella-del-Barrio
Patricia Comella-del-Barrio
OOOkoedoh Osazuwa
Okoedoh Osazuwa
JDJose Dominguez
Jose Dominguez
Background: Tuberculosis (TB) remains a leading cause of death worldwide, with major diagnostic challenges in low-resource settings. Urine-based lipoarabinomannan (LAM) assays provide a non-invasive option, particularly for people living with HIV who may struggle to produce sputum. Fujifilm has developed a second-generation SILVAMP TB LAM assay (FujiLAM v.2) to improve diagnostic performance. This study aimed to evaluate the diagnostic accuracy of FujiLAM v.2 among Nigerian adults with presumptive TB and directly compare it with the first-generation assay (FujiLAM v.1) using the same set of urine samples. Methods: We conducted a retrospective analysis among Nigerian adults with presumptive TB (n = 178). Stored urine samples collected in Abuja were retested with FujiLAM v.2 and compared with results previously obtained using FujiLAM v.1 on the same specimens. Xpert MTB/RIF and culture served as the reference standard. Sensitivity, specificity, agreement with the reference standard (Cohen’s Kappa), and differences (McNemar’s test) were assessed. Results: FujiLAM v.2 demonstrated sensitivity of 58.3% and specificity of 97.3%, comparable to FujiLAM v.1 (58.3% and 98.0%, respectively). No significant differences were found between test versions across TB or HIV subgroups (p > 0.05). Overall agreement between assays was 97.1% (κ = 0.80). Conclusions: FujiLAM v.2 showed diagnostic performance consistent with the first-generation assay, with similar sensitivity and specificity to the earlier version. These findings support its potential as a rapid, non-sputum-based diagnostic tool to complement TB testing in resource-limited settings. Further studies are needed to assess its implementation within TB diagnostic algorithms, including studies with multiple production lots.